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ABSTRACT 
Pharmacists and student pharmacists can play an important role in providing clinical preventive services as specified by the United 
States Preventive Services Task Force (USPSTF). The USPSTF guidelines provide evidence-based recommendations about clinical 
preventive services for the general population. The purpose of this paper is to provide information to pharmacists and student 
pharmacists developing and implementing preventive health care services. Examples of successful pharmacy-based programs are also 
provided. Pharmacists and student pharmacists can provide preventive health care interventions by conducting screenings, providing 
education, and making referrals. 
 
 
 
 
INTRODUCTION 
Preventive health care aims to improve health through 
prevention, early detection, and appropriate treatment of 
diseases. The United States Preventive Services Task Force 
(USPSTF) guidelines provide evidence-based recommendations 
about clinical preventive services for the general population. 
The USPSTF is an independent panel of national experts in 
prevention and evidence-based medicine that strives to 
improve the health of Americans through recommendations 
related to screening, counseling, and preventive medicine.   
Recommendations that are classified as A (high certainty of 
benefit) or B (high certainty of moderate benefit or moderate 
certainty that the benefit is moderate to substantial) should be 
routinely provided to all individuals within the defined patient 
population.1  Increasing emphasis is being placed on provision 
of preventive services, particularly with the implementation of 
the Patient Protection and Affordable Care Act (PPACA), which 
requires that health care insurers cover the cost of preventive 
services with no cost sharing.2   
 
The USPSTF guidelines, national disease state guidelines, and 
literature describing the implementation of services in 
pharmacies can be used by pharmacists and student 
pharmacists as resources to help develop and implement new  
 
 
 
services. Pharmacists and student pharmacists can deliver 
preventive health care interventions through conducting 
screenings, providing education, and making referrals.  The 
purpose of this paper is to share examples and provide 
implementation guidance for pharmacists and student 
pharmacists interested in adopting USPSTF A and B 
recommendations in the general, non-pregnant, adult 
population.3 The examples highlighted in this paper are not 
exhaustive, but are meant instead to provide a diverse range of 
instances in an effort to stimulate ideas for similar or 
extrapolated services that pharmacists and student 
pharmacists could provide to advance population health.  
 
Opportunities for pharmacists and student pharmacists to 
conduct screening and provide education and referrals based 
on current USPSTF recommendations (through November 30, 
2016) to the general, non-pregnant, adult population are 
summarized in Tables 1 and 2.  The reader should note that the 
USPSTF defers recommendations regarding immunizations to 
the Centers for Disease Control and Prevention's (CDC) Advisory 
Committee on Immunization Practices (ACIP).  Additionally, the 
USPSTF provides recommendations for pregnant women and 
children/adolescents, which are outside of the scope of this 
paper. 
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PHARMACY-BASED PREVENTIVE SERVICES 
 
Alcohol misuse: screening and counseling 
 
Topic Alcohol misuse 
Target population Adults 18 years of age and older 
Recommendation Screen for alcohol misuse and provide persons engaged in risky or hazardous drinking 
with behavioral counseling interventions to reduce alcohol misuse 
Implementation considerations 
          Supplies and protocols ● Alcohol misuse screening tool such as: Alcohol Use Disorders Identification Test 
(AUDIT), Alcohol Use Disorders Identification Test – Consumption (AUDIT-C), or a 
single question screening (e.g., “How many times in the past year have you had 5 [for 
men] or 4 [for women and all adults older than 65] or more drinks in a day?” 
● Protocol to connect patients, including those without a primary care provider, to an 
appropriate health care professional for diagnosis, treatment, and follow-up 
          Guidelines USPSTF recommendation: Alcohol misuse: Screening and behavioral counseling 
interventions in primary care 
 
Alcohol-use disorders: Diagnosis, assessment and management of harmful drinking and 
alcohol dependence 
Clinical pearls 
● Risky alcohol use is defined as more than 4 drinks on any day or 14 drinks per week for men or more than 3 drinks on any 
day or 7 drinks per week for women. 
● The alcohol misuse screening tools take between 1-5 minutes to administer and have adequate sensitivity and specificity. 
● Behavioral counseling interventions may be face-to-face, web-paged, via telephone or use written self-help materials.  
Examples of cognitive behavioral strategies include action plans, drinking diaries, stress management, and problem 
solving.  Interactions that occur more than one time and are between 6-15 minutes each have the best evidence of 
effectiveness while interventions less than 5 minutes in length have limited effect. 
 
 
Example: 
A study conducted in London, England showed that those with hazardous drinking behavior who participated in a 5-minute counseling 
session with a community pharmacist reduced drinking by 10%.  In this pilot study, 40 participants completed a drink diary and 
answered questions regarding their alcohol use at a community pharmacy using a validated tool from the World Health Organization.  
Pharmacists reviewed the results of the diary and tool with the participant in either a 5- or 15-minute counseling session, asked the 
patient how he/she felt about personal drinking habits, and provided information about the harmful effects of alcohol. Participants 
completed another drink diary one week later.  Participants who had identified hazardous drinking behaviors had reduced alcohol 
consumption by an average of 2.8 units per week. The length of the counseling session had no significant effect on alcohol 
consumption.4  
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Aspirin preventive medication 
 
Topic Aspirin use 
Target population Adults aged 50 to 59 years who have a 10% or greater 10-year cardiovascular risk, are not 
at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to 
take low-dose aspirin daily for at least 10 years 
Recommendation Low-dose aspirin use is recommended for prevention of cardiovascular disease and 
colorectal cancer 
Implementation considerations 
          Supplies and protocols ● Risk Assessment tools: 10-year risk of heart attack in men 
          Guidelines USPSTF recommendation: Prevention of cardiovascular disease with aspirin 
 
Clinical pearls 
● Aspirin is a salicylate derivative with antiplatelet and non-steroidal anti-inflammatory effects used in primary prevention 
of myocardial infarctions in men and ischemic strokes in women. 
● The mechanism of sex related differences is unknown, however, there appear to be differences in aspirin metabolism, 
differences in rates of myocardial infarction and stroke, and aspirin resistance. 
● A pharmacist can play a role in identifying patients at high risk of cardiovascular events.  Factors such as upper 
gastrointestinal complications, non-steroidal anti-inflammatory drug use, anticoagulant use, and overall cardiovascular 
health can help guide the decision to start aspirin.  
● The risks and benefits of continued therapy should be revisited at least every 5 years.  
● Aspirin 81 mg daily or 325 mg every other day is recommended; higher doses are not more effective but do increase the 
risk of bleeding. 
● Concurrent use of non-steroidal anti-inflammatory drugs (NSAID) and/or anticoagulant medications may increase upper 
gastrointestinal (GI) bleeding risk.  
● To ensure aspirin’s cardiovascular protective effects and prevent interactions, separate aspirin and NSAIDS by at least 2 
hours. 
 
 
Example: 
A study was done in 8 New York state community pharmacies to determine whether a program administered by student pharmacists 
could increase the number of patients with diabetes receiving aspirin therapy.  Student pharmacists completing an advanced practice 
pharmacy experience (APPE) in 1 of the 8 locations completed assessment sheets for each patient, faxed recommendations to 
physicians as needed, and counseled patients as appropriate.  Eighty-two percent of physicians contacted with recommendations 
responded to the student pharmacists, and aspirin therapy was initiated in 67% of eligible patients.5 
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Blood pressure screening 
 
Topic Blood pressure screening 
Target population Adults 18 years and older 
Recommendation Conduct screening 
Implementation considerations 
          Supplies and protocols ● Sphygmomanometer  
● Protocol to connect patients, including those without a primary care provider, to an 
appropriate health care professional for diagnosis, treatment, and follow-up 
          Guidelines USPSTF recommendation: Blood pressure in adults (hypertension): screening 
 
Evidence-based guideline for the management of high blood pressure in adults, 2014 
Clinical pearls 
● High blood pressure increases the risk of heart attacks, strokes, kidney failure, and death.  Treatment lowers the risk the 
complications. 
● High blood pressure is usually defined as ≥140/≥90 mmHg. 
● Nonpharmacologic treatments include reducing sodium intake, potassium supplementation, increased physical activity, 
weight loss, stress management, and reduced alcohol intake. 
● Factors that should be taken into account when deciding whether to initiates pharmacotherapy include blood pressure, 
age, and comorbid conditions.   
● The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before 
starting treatment.   
 
 
Example: 
The impact of pharmacy-based screening for high blood pressure was demonstrated by a project at a community pharmacy in Iowa.  
All individuals aged 18 and older who came into the pharmacy during the time period of the project were offered a blood pressure 
screening at no cost. Individuals were referred to their primary care providers (PCP) if the reading was high.  Sixty-two percent of 
individuals screened had blood pressure readings greater than 140/90 mm Hg, and 36% of those referred to a PCP had a medication 
change.6 
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Breastfeeding counseling 
 
Topic Breastfeeding counseling 
Target population Pregnant women and new mothers 
Recommendation Provide interventions during pregnancy and after birth to support breastfeeding 
Implementation considerations 
          Supplies and protocols ● Patient resources, such as those from The U.S. Department of Health and Human 
Services Office on Women’s Health, the Office of the Surgeon General, or La Leche 
League International.  
          Guidelines USPSTF recommendation: Primary care interventions to support breastfeeding 
 
Policy statement from the American Academy of Pediatrics on breastfeeding and the use 
of human milk 
Clinical pearls 
• Breastfeeding provides benefits for both the child (e.g. reduced risk of acute otitis media, asthma, diabetes) and the nursing 
mother (e.g. reduced risk of breast cancer, ovarian cancer, type 2 diabetes). 
• Education should be focused on increasing both rates and duration of breastfeeding. 
• Educational interventions can include discussing the benefits of breastfeeding, providing practical support and advice on how 
to breastfeed, and providing psychological support. 
• Pharmacists can provide direct education to patients, as well as provide referrals to other breastfeeding support networks. 
• Breastfeeding is contraindicated in certain maternal and fetal conditions and circumstances, such as certain medication use. 
Additionally, not all women are able to breastfeed. Therefore, individual factors and preferences must be considered. 
 
 
Example: 
The Well Babies at Walgreens program provided breastfeeding support for patients at Indiana Walgreens pharmacies. A professional 
lactation consultant met with patients in private rooms at the pharmacy. Pharmacists at those stores also received training to enhance 
their knowledge about breastfeeding so they would be able to appropriately respond to questions from patients who arrived at the 
pharmacy at times when the lactation consultant was not present.7 
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Depression screening 
 
Topic Depression screening 
Target population General adult population, including pregnant and postpartum women. 
Recommendation Screening should be implemented with adequate systems in place to ensure accurate diagnosis, 
effective treatment, and appropriate follow-up. 
Implementation considerations 
         Supplies ● Depression screening tool, such as the Patient Health Questionnaire (PHQ-9)   
● Protocol to connect patients, including those without a primary care provider, to an appropriate 
health care professional for diagnosis, treatment, and follow-up 
● Protocol to assess patient risk of suicidality and plan to ensure access to emergency services  
         Guidelines USPSTF recommendation: Screening for depression in adults 
 
Adult depression in primary care 
Clinical pearls 
● Persons at increased risk for depression include those with other psychiatric disorders, family history of depression, 
chronic medical diseases, unemployed, have lower socioeconomic status, or female gender. 
● PHQ-9 is a nine question assessment that can be completed in less than 5 minutes.  A score of five or more indicates that 
depression is possible; therefore a referral for diagnosis, treatment, and follow-up should be provided. 
● Some clinicians screen all patients using the first two items of the PHQ-9.  If the patient responds positively to either 
question, the PHQ-9 is given. 
● All individuals who may interact with patients should have clear instructions regarding their role when interacting with a 
suicidal patient. 
● Treatment for depression may include psychotherapy and/or medications based on the severity of the symptoms, 
psychosocial stressors, comorbid conditions, and patient preference.   
 
 
Example: 
Pharmacists in Ohio developed, implemented, and evaluated a program to screen patients aged 18 years or older for depression in 32 
community pharmacies located in grocery stores.  The pharmacists utilized the Patient Health Questionnaire (PHQ). For patients 
screening positive on the PHQ, the longer PHQ-9 was then administered. Patients screening positive on the PHQ-9 were then referred 
to their PCP. Pharmacists followed-up with these patients.  Of the 3,726 patients screened, 25% met criteria per the PHQ-9 to be 
referred to their PCP; upon pharmacist follow-up, 60% of those had begun or had changes in therapy.  Pharmacists identified 5 patients 
who had suicidal thoughts and referred them for urgent treatment.8 
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Diabetes screening 
 
Topic Diabetes mellitus type 2 screening 
Target population Adults with elevated blood pressure 
Recommendation Screen for type 2 diabetes in asymptomatic adults with sustained blood pressure (either 
treated or untreated) greater than 135/80 mmHg. 
Implementation considerations 
         Legal requirements    Obtain a Clinical Laboratory Improvement Amendments (CLIA) waiver through the State 
Department of Health and complete a Form 116 
         Supplies and protocols ● Appropriately sized blood pressure cuff 
● Blood glucose testing supplies, such as a glucometer and test strips or hemoglobin 
A1C testing device 
● Protocol to connect patients, including those without a primary care provider, to an 
appropriate health care professional for diagnosis, treatment, and follow-up 
● Patient resources, such as from the National Diabetes Education Program 
         Guidelines USPSTF recommendation: Diabetes mellitus (type 2) screening 
 
American Diabetes Association guidelines 2016 
Clinical pearls 
● This recommendation applies to people without symptoms of diabetes, such as polyuria, polyphagia, or polydipsia. 
Symptomatic individuals should be screened regardless of blood pressure.  
● Screening tests include fasting plasma glucose (diabetes is defined as ≥ 126 mg/dL), 2-hour postload plasma glucose 
(≥200 mg/dL), and hemoglobin A1C ≥ 6.5%). The fasting plasma glucose test is the easiest, fastest, and most economical 
to perform.  It is recommended that this test be repeated on another day before a diagnosis is made, especially if the 
results are borderline. 
● Long term complications of diabetes mellitus type 2 include both microvascular (e.g., retinopathy, nephropathy, 
neuropathy) and macrovascular (e.g., peripheral vascular disease, coronary artery disease, and cerebrovascular disease) 
events. 
● Metabolic syndrome occurs when a person has three or more of the following: abdominal obesity, elevated trigylcerides, 
low HDL, elevated blood pressure and elevated fasting glucose.  This syndrome increases the risk of cardiovascular 
events. 
 
 
Example: 
A pilot test was performed in Australia to determine the utility of community pharmacists in screening patients for type 2 diabetes 
and referring patients as needed to PCPs.  Thirty pharmacies participated in the program and within 3 months had screened 1286 
patients using either a checklist or a blood glucose test.  Patients at risk for type 2 diabetes were determined by both methods and 
referred to PCPs as appropriate.9   
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Falls prevention in older adults 
 
Topic Falls prevention in older adults 
Target population Community-dwelling adults aged 65 years or older who are at increased risk for falls 
Recommendation Exercise or physical therapy and vitamin D supplementation 
Implementation considerations 
          Supplies and protocols ● Protocol to connect patients, including those without a primary care provider, to an 
appropriate health care professional for evaluation and follow-up 
          Guidelines USPSTF recommendation: Falls prevention in older adults: Counseling and preventive 
medication 
 
Centers for Disease Control and Prevention: Injury prevention & control 
Clinical pearls 
● Factors to evaluate include history of falls, mobility issues, and the Get-Up-and-Go test which is a timed test that requires 
rising from a chair, walking, and sitting back down. 
● The American Geriatric Society recommends evaluating fall risk annually. 
● It is recommended that adults participate in at least 150 minutes per week of moderate-intensity or 75 minutes per week of 
high intensity exercise, as well as strength activities twice weekly, and balance training at least three days per week. 
● The recommended amount of vitamin D supplementation is 600 units per day for adults 51-70 years of age and 800 units for 
adults older than 70 years or those at high risk for falls. 
● The American Geriatrics Society recommends evaluating all prescription and over-the-counter agents to determine whether 
they may increase the risk of falls. 
 
 
Examples: 
While the USPSTF stops short of recommending further specific interventions related to other medications, other peer-reviewed 
recommendations, as well as a report by the CDC, suggest additional interventions for fall prevention that is targeted at medication 
assessment by a pharmacist or healthcare professional, with medication adjusted or modified by a physician or nurse practitioner.10,11  
Examples of pharmacist interventions have been described in the literature, specifically noting the ability of a pharmacist to intervene 
to prevent falls through the use of an electronic health record (EHR) or through the medication therapy management (MTM) process.12-
15  
 
  
Idea Paper PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                               2017, Vol. 8, No. 1, Article 11                  INNOVATIONS in pharmacy     9 
 
 
Folic acid supplementation 
 
Topic Folic acid supplementation to prevent neural tube defects 
Target population All women of childbearing potential 
Recommendation All women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 
mg (400 to 800 mcg) of folic acid. 
Implementation considerations 
         Supplies Free materials about folic acid can be obtained from:  
 
• National Birth Defects Prevention Network: National Birth Defects Prevention Month 
• Centers for Disease Control and Prevention: CDC-INFO on Demand: Publications  
• National Birth Defects Prevention Network: Folic Acid Awareness Week 
Guidelines USPSTF recommendation: Folic acid to prevent neural tube defects 
Clinical pearls 
● Sufficient amounts of folic acid before conception and during early pregnancy has been shown to reduce the risk of 
neural tube defects (NTD), such as anencephaly and spina bifida, by 50-70%.  
● For most women of childbearing potential, 400-800 micrograms daily is the recommended daily dose.  
● While there are food sources of folic acid, most women do not get enough folic acid through diet alone. 
● Nearly half of all pregnancies in the U.S. are unintended. Therefore, all women capable of becoming pregnant should be 
advised to take a multivitamin or folic acid tablet containing 400-800 micrograms of folic acid daily. 
● Women with certain risk factors should be advised to take higher doses in the months prior to conception. This includes 
women with diabetes (usually 4-5 mg/day), using anti-epileptic drugs (usually 4 mg/day), or who have experienced a 
previous NTD-affected pregnancy (usually 4 mg/day). 
● In the U.S., disparities in rates of NTD persist with Hispanic women experiencing a greater number of pregnancies 
affected by NTD when compared to non-Hispanic white women.  One reason is that Hispanic women are less likely to eat 
foods fortified with folic acid. 
 
 
Example: 
A partnership was formed between a managed Medicaid plan, an MTM platform, and academic investigators to develop and 
implement education-based targeted medication reviews (TMRs) focused on three areas of preconception care, including folic acid 
use.  Community pharmacists in Ohio who participated in the MTM platform and had a female patient in the managed Medicaid plan 
provided education on folic acid use, provided necessary follow-up with her PCP, documented, and billed for this service.  Within 19 
weeks of launching the TMRs, 1149 pharmacists in 818 pharmacies had participated in the program.  Over 1400 TMRs for education 
about folic acid use were completed with a 69% success rate.16 
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Healthful diet and physical activity behavioral counseling 
 
Topic Healthful diet and physical activity behavioral counseling 
Target population Adults 18 years and older who are overweight or obese and who have additional 
cardiovascular disease risk factors (hypertension, dyslipidemia, impaired fasting glucose, or 
metabolic syndrome). 
Recommendation Offer or refer individuals to intensive behavior counseling interventions to promote healthful 
diet and physical activity 
Implementation considerations 
          Supplies and protocols • Online body mass index (BMI) calculator or BMI chart 
          Guidelines USPSTF recommendation: Healthful diet and physical activity counseling 
 
Managing overweight and obesity in adults: Systematic evidence review from the obesity 
expert panel, 2013 
Clinical pearls 
● Overweight is defined as a BMI of 25.0-29.9 and obesity is defined as a BMI of 30.0 and higher. 
● A reduction in calories of 500-1,000 kcal/day can help achieve a weight loss of 1-2 pounds /week 
● A low calorie diet of 1,000-1,200 kcal/day is reasonable for most women, while a low calorie diet of 1,200-1,800 kcal/day 
should be chosen for most men for weight loss. 
● Fewer than 30% of daily calories should come from fat, with saturated fatty acids making up only 8-10% of total calories. 
● Lean animal and plant protein should make up around 15% of total daily calories. 
● Total carbohydrates should make up about 55% of daily calories.  Generally 20-35g of dietary fiber should be consumed. 
● 30-45 minutes of physical activity 3-5 days/week should be encouraged initially, with a long-term goal of ≥30 minutes of 
moderate-intensity physical activity on most, if not all, days of the week 
● In order to help patients change behaviors, it is essential to build a partnership with the patient and make the patient an 
active participant in setting goals regarding behavioral changes. 
● Helping patients monitor progress and focus on positive steps toward achieving goals can help keep patients motivated 
to continue pursuing dietary and exercise goals. 
 
 
Example: 
A study was performed to evaluate the effectiveness of an education intervention program provided by pharmacists and student 
pharmacists to female patients of an Ohio community health center with an on-site 340B pharmacy. The educational intervention 
consisted of a pre-test, 10-minute educational counseling session, post-test, and satisfaction survey. A pharmacist or student 
pharmacist met with each patient individually. The patient received education about cardiovascular disease; risk factors; lifestyle 
modifications such as nutrition, physical activity, and smoking cessation; and symptoms of myocardial infarction. Patients were also 
screened for hypertension and/or hyperlipidemia. Patient-friendly educational materials and information on available pharmacy 
clinical services were provided to patients as needed.  After the counseling session, correct responses for 6 of 8 knowledge-based 
questions were statistically significantly improved from pre-test to post-test. Ninety-seven percent of patients indicated the program 
was “useful” or “very useful”.17 
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Human immunodeficiency virus (HIV) and Hepatitis C screening 
 
Topic Human immunodeficiency virus (HIV) infection screening 
Target population Adolescents and adults 15-65 years of age 
Recommendation One time screening plus repeat screenings for those at high risk 
Implementation considerations 
          Legal requirements Follow current federal, state, and local laws regarding reporting of cases 
 
 
Obtain a Clinical Laboratory Improvement Amendments (CLIA) waiver through the State 
Department of Health and complete a Form 116 
          Supplies and protocols ● Protocol for CLIA-waived screening testing to take place in the community pharmacy 
● Protocol to connect patients for confirmatory testing, including those without a 
primary care provider, to an appropriate health care professional for diagnosis, 
treatment, and follow-up as appropriate 
          Guidelines USPSTF recommendation: HIV infection: Screening 
 
Centers for Disease Control and Prevention HIV screening and testing 
Clinical pearls 
● Active injection drug users and men who have sex with men are considered to be at very high risk for new HIV infection. 
● Behavioral risk factors include unprotected intercourse; having sexual partners who are HIV-infected, bisexual, or 
injection drug users; or exchanging sex for drugs or money 
● No optimum time interval for HIV screening exists. Consider screening at least annually for those at very high risk, and 
those at increased risk may be screened every 3-5 years, but use clinical judgment and most recent literature when 
recommending screening intervals. 
● Positive rapid screening tests should be confirmed using conventional diagnostic methods. 
Topic Hepatitis C screening 
Target population Adults born between 1945 and 1965 and persons at high risk for infection 
Recommendation Screening for persons at high risk for infection and a one-time screening for adults born 
between 1945 and 1965 
Implementation considerations 
          Legal requirements Follow current federal, state, and local laws regarding reporting of cases 
 
Obtain a Clinical Laboratory Improvement Amendments (CLIA) waiver through the State 
Department of Health and complete a Form 116 
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          Supplies and protocols ● CLIA-waived hepatitis C test 
● Protocol to connect patients for confirmatory testing, including those without a 
primary care provider, to an appropriate health care professional for diagnosis, 
treatment, and follow-up as appropriate 
          Guidelines USPSTF recommendation: Hepatitis C: Screening 
 
HCV guidance: Recommendations for testing, managing, and treating hepatitis C 
Clinical pearls 
● Hepatitis C is the most common chronic blood borne pathogen in the United States 
● High risk populations include past or present injection drug use, sex with an injection drug user, or blood transfusion 
before 1992 
● Anti-HCV antibody testing must be followed by confirmatory polymerase chain reaction testing in order to detect chronic 
hepatitis C infection 
● There is inadequate evidence to support knowledge of positive status as a means for reducing high-risk behaviors 
● Potential harms for screening include anxiety, patient labeling, and feelings of stigmatization 
● Medications are available manage and potentially cure hepatitis C in some patients 
 
 
Examples:  
Opportunity to screen for chronic infectious diseases, such as hepatitis C and human immunodeficiency virus (HIV), is gaining attention 
in community pharmacies.18  For example, a pilot was conducted by the CDC where confidential HIV tests were offered at 21 different 
sites (18 of which were community pharmacies) in the U.S.19  Following a standardized training program, personnel performed both 
on- and off-site testing, resulting in 1.6% of tests as reactive and therefore necessitating referral and confirmatory testing. Staff-patient 
interaction time required a median 4 minutes for pretest counseling/consent, 3 minutes of posttest counseling, and 23 minutes waiting 
for test results (when testing staff could be engaged in other work activities).  The FDA’s approval of the first oral HIV home test kit 
represents an additional option for enhancing patient access as it provides a result within 20 minutes.20 Pharmacists have indicated 
that patient counseling (explaining the testing procedure, laying the foundation of the pharmacist-patient relationship, etc.) would be 
valuable when the OTC HIV test is purchased.21   
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Intimate partner violence screening 
 
Topic Intimate partner violence screening 
Target population Women of childbearing age 
Recommendation Screen women of childbearing age for intimate partner violence (IPV), such as domestic 
violence, and provide or refer women who screen positive to intervention services 
Implementation considerations 
Legal  considerations Providers should be aware of state and local reporting requirements and be familiar with 
requirements in the privacy regulations of the federal Health Insurance Portability and 
Accountability Act, which require that patients be advised on health information use and 
disclosure practices. 
Supplies and protocols • Screening instruments such as Hurt, Insult, Threaten, Scream (HITS; English and 
Spanish versions); Ongoing Abuse Screen/Ongoing Violence Assessment Tool (OAS/OVAT); 
Slapped, Threatened, and Throw (STaT); Humiliation, Afraid, Rape, Kick (HARK); Modified 
Childhood Trauma Questionnaire–Short Form (CTQ-SF); and Woman Abuse Screen Tool 
(WAST). 
         Guidelines USPSTF recommendation: Intimate partner violence  
 
ACOG Committee Opinion No. 518: Intimate partner violence 
Clinical pearls 
● The term “intimate partner violence” describes physical, sexual, or psychological harm by a current or former partner or 
spouse. 
● While all women are at potential risk for abuse, factors that elevate risk include young age, substance abuse, marital 
difficulties, and economic hardships. 
● Interventions may include counseling, home visits, information cards, referrals to community services, and mentoring 
support which may be provided by clinicians, nurses, social workers, non-clinician mentors, or community workers.  
Counseling generally includes information on safety behaviors and community resources. 
 
 
Examples:  
Surveys have assessed attitudes and needs of patients, pharmacists, and student pharmacists regarding feasibility and acceptability 
of screening for intimate partner violence (IPV) in pharmacies. For example, an online survey of 60 women in Mississippi showed that 
33% thought IPV screening should occur in pharmacies.22  A survey conducted with U.S. community pharmacists found a willingness 
to conduct IPV screening with targeted patients and an interest in continuing education on IPV.23  In another study, nearly 90% of 
student pharmacists from 1 school in New York surveyed thought IPV was “relevant” to their pharmacy careers and specified areas 
such as legal and liability issues as educational needs.24 
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Obesity screening and management 
 
Topic Obesity screening and management 
Target population All adults 
Recommendation Screen all adults for obesity. Clinicians should offer or refer patients with body mass index 
(BMI) of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions 
Implementation considerations 
          Supplies and protocols ● Online body mass index (BMI) calculator or BMI chart 
● Protocol to connect patients, including those without a primary care provider, to an 
appropriate health care professional for diagnosis, treatment, and follow-up 
          Guidelines USPSTF recommendation: Obesity in adults 
 
Managing overweight and obesity in adults: Systematic evidence review from the obesity 
expert panel, 2013 
Clinical pearls 
● Screening may include evaluating BMI and/or waist circumference.  Overweight is classified as a BMI of 25.0-29.9 kg/m2 
and obese is ≥30 kg/m2.  A high waist circumference is ≥40 inches for men and ≥35 inches for women. 
● Weight loss therapy is recommended for patients with BMI ≥ 25 kg/m2 or a high-risk waist circumference plus two or 
more risk factors, including hypertension, diabetes mellitus (type 2), family history or established cardiovascular disease, 
cigarette smoking, high LDL cholesterol, low HDL cholesterol, impaired fasting glucose, age (male ≥ 45 years, female ≥ 55 
years), and sleep apnea.  
● Intensive, multicomponent behavioral interventions can lead to an average weight loss of 8.8 to 15.4 pounds while 
improving glucose tolerance and risk factors for cardiovascular disease. 
● When weight loss is not achievable, the goal should be to prevent further weight gain; this may be appropriate for 
overweight patients (BMI 25–29.9 kg/m2) not otherwise at high risk. 
● Dietary therapy: caloric intake reduction by 500 – 1,000 calories per day (kcal/day)  
● Physical activity: moderate intensity exercise ≥ 30 minutes on most days increased slowly with care to avoid injury; 
reduces risk of CHD, lowers body fat, and prevents decrease in muscle mass due to weight loss. 
● Behavior therapy: stress management, stimulus control, and cognitive restructuring. 
● Pharmacotherapy: may be appropriate if patient failed weight loss after 6 months only and patient has BMI ≥ 30 kg/m2 or 
BMI > 27 kg/m2 with risk factors 
● Surgery: may be appropriate for well-informed and motivated patients with severe obesity (BMI ≥ 40 kg/m2) or a BMI ≥35 
kg/m2 with serious comorbid conditions. 
 
 
Examples:  
Published studies have shown the impact of pharmacists in screening patients for obesity, though usually the screening was conducted 
as part of a broader program targeting diabetes or cardiovascular disease.  Studies have also examined potential models for 
pharmacists to deliver services to assist in weight loss, either independently or as part of an interdisciplinary team.  Several successful 
pharmacy-based weight loss programs have been described in the U.S. and other countries.25 
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Osteoporosis screening 
 
Topic Osteoporosis screening 
Target population Women 65 years and older and in younger women whose fracture risk is equal or greater 
than that of a 65-year-old white woman who has no additional risk factors 
Recommendation Screen for osteoporosis 
Implementation considerations 
          Supplies and protocols ● Bone mineral densitometer  
● Protocol to connect patients, including those without a primary care provider, to 
an appropriate health care professional for diagnosis, treatment, and follow-up 
as appropriate 
● Osteoporosis patient education 
● Protocol to assess patient risk of falls (e.g., STEADI) and plan to ensure proper 
medication administration and lifestyle changes (NOF Prevention) 
          Guidelines USPSTF recommendation: Screening for osteoporosis in adults 
 
AACE Medical guidelines for clinical practice for diagnosis and treatment of 
postmenopausal osteoporosis 
 
National Osteoporosis Foundation Clinician’s guide  
Clinical pearls  
● Health providers should counsel patients on osteoporosis non-modifiable risk factors (i.e. age, gender, and history of 
fractures) and modifiable risk factors (i.e. proper intake of calcium and vitamin D, regular weight bearing exercise, 
smoking cessation, body mass index, nutrition, estrogen deficiency, frequency of falls, and decreased alcohol intake) 
● T-scores compare a patient’s bone density to that of a healthy 30-year old. Lower T scores are indicative of lower bone 
density.  
● Z-scores compare a patient’s bone density to that of others of the same age, sex, and weight. The Z-score tends to be less 
negative than the T-score and is merely used for relative comparative measures to peers, NOT used to diagnose 
osteoporosis or osteopenia.  
● Upon screening for osteoporosis, a T-score of less than -1 necessitates referral for diagnosis, treatment, and follow-up to 
primary care services.  
● Treatment for osteoporosis may include lifestyle changes and/or medications based on the severity, history of fractures, 
and patient preference.   
 
 
Examples:  
Published literature has documented the potential opportunities to deliver osteoporosis screenings in U.S. pharmacies.  Several 
different approaches can be used; most pharmacies have reported a fee-for-service model to collect a cash payment from screening 
participants, which often ranges anywhere from $10-$35.26-28  Patients can self-refer to the service or can be referred by their PCP.27-
29   Patients found to be high risk, according to the specific bone densitometer used, should be referred for follow up and further 
screening with a physician.   
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Sexually transmitted infections behavioral counseling 
 
Topic Sexually transmitted infections: behavioral counseling 
Target population Sexually active adolescents and adults who are at increased risk for sexually transmitted 
infections (STIs). Also included are adults with current STIs or other infections, persons 
with multiple sex partners, or persons who do not use condoms  
Recommendation Refer to intensive behavioral counseling interventions to prevent STIs 
Implementation considerations 
          Supplies and protocols Follow current federal, state, and local laws regarding reporting of cases 
          Guidelines USPSTF recommendation: Sexually transmitted infections: Behavioral counseling 
  
Centers for Disease Control and Prevention Sexually transmitted diseases treatment 
guidelines, 2015 
Clinical pearls 
● Behavioral and psychosocial services are an integral part of holistically assisting individuals suffering from STIs.  
● Behavioral counseling interventions lasting at least 30 minutes and providing basic information about STIs and STI 
transmission are most effective. It is also important to assess the risk for transmission and provide patient specific 
recommendations such as condom use, safe sex, problem solving, and goal setting techniques, as appropriate.  
● Patients who test positive for an STI should be counseled regarding behavioral, psychosocial and medical implications at 
the point of care or referred for timely medical care.  
● Referrals to substance abuse programs must be discussed and provided. 
● Depending on state laws, partners may be required to be notified regarding the potential infection and connected with 
resources available for screening, post-exposure prophylaxis therapy, and additional medical care.  Pharmacists should 
be familiar with the state laws governing the management of sex and injection-drug partners. 
 
 
Example:  
In a study performed in Lima, Peru, pharmacy workers were randomized to either receive training and materials for prevention and 
management of sexually transmitted infections (STI) (intervention group) or management of diarrhea (control group).  Pharmacy 
workers received education on STI/HIV prevention counseling and information on 4 STI conditions.  They also received supportive 
materials including referral cards that patients could give to their partners and condoms that could be distributed to patients.  Through 
the study, it was determined that training of pharmacy workers was feasible and significantly improved their practices in regards to 
prevention and management of STI.30 
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Skin cancer behavioral counseling 
 
Topic Skin cancer behavioral counseling 
Target population Children, adolescents, and young adults ages 10 to 24 years who have fair skin  
Recommendation Counsel individuals about minimizing their exposure to ultraviolet radiation to 
reduce risk for skin cancer 
Implementation considerations 
          Supplies and protocols • CDC Skin Cancer Prevention Fact sheets  
• American Academy of Dermatology Free resources 
          Guidelines USPSTF recommendation: Skin cancer behavioral counseling  
Clinical pearls 
● Behavior change interventions should be focused on activities proven as effective in reducing ultraviolet (UV) radiation 
exposure.  
● UV radiation results from exposure to the sun during midday hours and from artificial sources including indoor tanning.  
● Behaviors to emphasize include the use of at least one ounce of broad-spectrum water resistant sunscreen with a sun-
protection factor of 15 or greater applied at least every 2 hours or after swimming/sweating, wearing protective clothing 
including hats, avoiding exposure to the sun during midday hours (10 a.m. to 3 p.m.), and never exposing oneself to 
indoor tanning.  
● Patients should utilize all behaviors to minimize risk. 
● Sunscreen should not be used in infants under 6 months of age; protection from sun via shade, clothing, or by staying 
indoors should be recommended. 
 
 
Example:  
Pharmacists in 54 pharmacies from 3 large pharmacy chains in California were randomized to receive training regarding skin cancer 
prevention or no training.  After the intervention, skin cancer prevention counseling rates rose significantly among those pharmacists 
in intervention group (from 0% to 67%). In addition, over 10,000 educational brochures about skin cancer were distributed during the 
study period.31 
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Statin preventive medication 
 
Topic Statin use  
Target population Adults age 40-75 years with no history of CVD, 1 or more CVD risk factors, and a 
calculated CVD risk of 10% or greater (lesser evidence for CVD risk of 7.5-10%)  
Recommendation Use a low- to moderate-dose statin for the prevention of CVD events and mortality 
when: 1) age 40-75 years; 2) have 1 or more CVD risk factors (dyslipidemia, diabetes, 
hypertension, or smoking); AND 3) have a calculated 10-year risk of a cardiovascular 
event of 10% or greater. 
Implementation considerations 
          Legal requirements If you intend to perform point-of-care cholesterol testing as a part of a dyslipidemia 
risk factor assessment, obtain a Clinical Laboratory Improvement Amendments 
(CLIA) waiver through the State Department of Health and complete a Form 116 
          Supplies and protocols ● Access to the ASCVD Risk Estimator 
● Cholesterol machine and supplies for testing 
● Resources such as patient education 
● Protocol to connect patients, including those without a primary care 
provider, to an appropriate health care professional for diagnosis, 
treatment, and follow-up 
          Guidelines USPSTF Recommendation: Statin use for primary prevention of CVD 
 
ASCVD Risk estimator 
 
2013 ACC/AHA Guideline on the treatment of blood cholesterol 
Clinical pearls 
● Increased risk include any one of the following risk factors: dyslipidemia, diabetes, hypertension, or smoking 
● The goal is to reduce the risk of cardiovascular events. 
● Identification of dyslipidemia and calculation of 10-year CVD event risk requires universal lipids screening in adults aged 
40-75 years. 
 
 
Example: 
Given that the above recommendation on statin use were just released at the time of this writing, examples from the literature may 
not use this framework exactly. However, pharmacists have been participating in preventive care related to cholesterol management 
for many years. For example, pharmacists in a medical center in California were incorporated in a “walk-in” lipid screening program, 
where patients referred themselves to the service and paid an out-of-pocket fee of $20.  Of the patients screened, 34% had high values 
but had not been previously diagnosed with a lipid abnormality.  Overall, 50% of those screened required an intervention by the 
pharmacist.  Patients were referred to their PCP as needed for follow-up.31 Additional studies on lipid management by pharmacists 
have also been conducted with varied approaches, yet positive outcomes.  
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Tobacco use counseling and interventions 
 
Topic Tobacco use counseling and interventions 
Target population Adults 18 years and older 
Recommendation Ask about tobacco use and provide tobacco cessation interventions to those who 
use tobacco products.  
Implementation considerations 
          Supplies and protocols • Resources: patient education posters, patient education, SmokeFree website, 
1-800-QUIT-NOW (1-800-784-8669)  
• Patient referral information: Quitline cards or Fax-to-Quit forms  
• Protocol to connect patients, including those without a primary care provider, 
to an appropriate health care professional for further treatment and follow-up 
          Guidelines USPSTF recommendation: Tobacco use in adults 
 
AHRQ Treating tobacco use and dependence 
Clinical pearls  
● Techniques such as the 5A's or Ask-Advise-Refer are appropriate for primary care or pharmacy settings. Engaging 
pharmacy technicians to support and help initiative discussions on smoking cessation at drop-off, pick-up, and drive-thru 
areas may mitigate the increased pharmacist time spent on non-dispensing roles.  
● Nicotine withdrawal effects include: irritability, anxiety, difficulty concentrating, restlessness, increased appetite, 
impaired task performance, drowsiness, fatigue, sleep disturbances, and nicotine craving.  
● Peak nicotine withdrawal presents approximately 1 to 4 days after smoking discontinuation and effects diminish in 
intensity over 2-4 weeks. Nicotine craving may persist intermittently for months to years and may be triggered by 
stressful situations or observing others smoke.  
● A combination of both non-pharmacologic (counseling, abrupt cessation, hypnotherapy, acupuncture, etc.) and 
pharmacologic smoking cessation therapy is preferred if appropriate for the patient. Three FDA-approved pharmacologic 
therapies include nicotine replacement therapy (i.e. nicotine gum, patch, lozenge, nasal spray, and inhaler), psychotropic 
medications (i.e. bupropion), and partial nicotinic receptor agonists (i.e. varenicline).   
● Electronic cigarettes should not be recommended as tobacco cessation aids. 
 
Examples:  
Pharmacists can play an important role in decreasing tobacco use, either as part of a team or as a stand-alone service. Evidence shows 
that engagement of multiple health professionals increases readiness to quit smoking. 33  Previous studies have also demonstrated 
great success implementing smoking cessation programs in the community pharmacy setting. One popular tobacco cessation 
intervention model which addresses the lack of time barrier is the Ask-Advise-Refer (AAR) model.34 The ARR model includes asking 
patients about tobacco use, advising patients to quit, and referring patients to quitlines (1-800-QUIT-NOW) for further assistance. 
Pharmacy technicians can be involved in the Ask and Refer process where responsibilities could include asking patients about tobacco 
use, documenting interaction outcomes, notifying pharmacists of the need for patient interventions, and faxing completed referral 
forms to quitline services.35 
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Tuberculosis screening 
 
Topic Tuberculosis screening 
Target population Asymptomatic adults at increased risk for infection should be screened for latent 
tuberculosis infection (LTBI).  
 
Populations at increased risk for LTBI include persons who were born in, or are 
former residents of, countries with increased tuberculosis prevalence and persons 
who live in, or have lived in, high-risk congregate settings (e.g., homeless shelters 
and correctional facilities). As local demographic patterns may vary across the U.S., 
clinicians should consult their local or state health departments for more 
information about populations at risk in their community.  
 
Recommendation The USPSTF recommends screening for latent tuberculosis infection (LTBI) in 
populations at increased risk 
Implementation considerations 
          Supplies and protocols ● Appropriate supplies for testing (e.g., syringe, tuberculin purified protein 
derivative) 
● Protocol to connect patients, including those without a primary care provider, to 
an appropriate health care professional for diagnosis, treatment, and follow-up 
● Resources for health care providers and patients are available from the CDC 
          Guidelines USPSTF recommendation: Tuberculosis screening 
 
ATS/CDC/IDSA Tuberculosis treatment guidelines 
 
Clinical pearls 
● As many as 13 million people in the US have LTBI, which can become active and multiply.   
● Some patients will require a 2-step tuberculin skin test (TST), and pharmacists should be adequately trained to identify 
patients that meet criteria for the 2-step TST. 
● Screening with the TST requires that patients return 48-72 hours after administration of the skin test for results 
interpretation. 
● The interferon-gamma release assay (IGRA) test is a blood test for LTBI which may be useful in certain circumstances, such as 
when the patient may be unlikely to return for TST interpretation. 
● Positive results may necessitate reporting; follow-up with a qualified health care professional to evaluate need for treatment 
is highly important. 
 
Example:  
The success of community pharmacy-based tuberculosis (TB) testing was demonstrated in New Mexico, where pharmacists were given 
the authority to order, give, and evaluate tuberculin skin tests (TSTs). Over approximately a 2-year period, 25 pharmacists administered 
606 TSTs; a 3.1% positively rate was observed, and these patients were referred to physicians.36 
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OPPORTUNITIES FOR EDUCATION AND/OR REFERRAL 
Examples of USPSTF recommendations that pharmacists and 
student pharmacists could provide education and referrals for 
are outlined in Table 2 and include screenings for abdominal 
aortic aneurysms, BRCA, breast cancer, cervical cancer, 
chlamydial infection, colorectal cancer, gonorrhea, hepatitis B, 
lung cancer, and syphilis and prescribing breast cancer 
preventive medications. Typically, these services are outside of 
a pharmacists’ scope of practice or may not be feasible in a 
pharmacy setting.  However, pharmacists practicing in certain 
sites or under certain provisions (such as collaborative practice 
agreements, as described below) may be able to directly 
provide prescriptions or referrals, per scope of practice. 
 
Even if the service is not being offered directly in the 
pharmacy, there is an opportunity to provide education on the 
topic and facilitate referrals to clinics that do provide the 
service for patients who meet the criteria for the target 
populations specified by the USPSTF as good candidates for 
the service.  Pharmacists need to consider how they will 
identify patients in need of education and/or referral 
services.  For example, if a community pharmacy decided to 
implement a program related to colorectal cancer screening, a 
protocol may be developed so that a pharmacy technician 
adds a note in the computer system for all patients aged 50-75 
years.  When the note appears at the medication pick-up 
window, the pharmacist can discuss the screening with the 
patient.  The pharmacy may wish to post signs to make 
patients aware of the initiative.  Additionally, it may be useful 
to have patient-friendly literature available as well as a list of 
providers in the area who offer the service. 
 
IMPLEMENTATION STRATEGIES 
Health care professionals have access to a number of 
resources that may be helpful when considering 
implementation of preventive services.  The USPSTF website 
offers comprehensive, accurate, and up-to-date information 
for health professionals and patients regarding clinical and 
community preventive services. Recommendations can be 
sorted by document title, type of material, or recommendation 
title.37 The Agency for Healthcare Research and Quality (AHRQ) 
also provides an electronic Preventive Services Selector (ePSS) 
tool that can be used to access the latest USPSTF 
recommendations based on a patient’s age, gender, pregnancy 
and sexual activity status, and tobacco use. This tool allows a 
health care professional to quickly generate a comprehensive 
list of all USPSTF-recommended clinical preventive services for 
an individual patient. 38 
 
Although the need for preventive care is recognized and the 
pharmacists’ role in providing preventive care is clearly 
important, the implementation process can seem difficult.  As 
described in this paper, many examples of successful 
pharmacy-based preventive services exist.  These examples, as 
well as others found in the literature, often include discussions 
of labor, technology, time, and other resources needed for 
success in initiating a specific preventive service.  For instance, 
it may be wise to consider the potential for utilization of 
pharmacy technicians in the workflow and management of 
such programs to ensure efficiency and ease of 
implementation.39,40  As pharmacists look to expand non-
dispensing services offered, similar approaches to 
implementing preventive care services as those published in 
the literature can be followed.   
There may be innovative ways in which pharmacists can play a 
greater role in providing clinical preventive services. 
Pharmacists should be aware of different approaches to 
practice that allow them to perform at the highest ability of 
their training and education.41  For example, collaborative 
practice agreements (CPA) are one tool by which pharmacists 
develop formal practice relationships with other health care 
professionals.42,43 CPA allow pharmacists to collaborate with 
another health care professional in a way that allows practice 
beyond the pharmacist’s traditional scope of practice, but still 
within the training and education of that pharmacist. CPA have 
also been recommended as a pathway to new service 
implementation.44 While ideal elements of CPA have been 
developed, state laws and regulations regarding CPAs are 
inconsistent.42,43 
 
Opportunities to provide clinical preventive services also exist 
for pharmacists and student pharmacists who practice in novel 
settings. For example, Murphy et al. describe the 
implementation of a comprehensive preventive care program 
by pharmacists in the setting of an employee health and 
wellness clinic.  By using the ePSS tool, pharmacists accessed a 
list of all preventive services recommended for an individual.  
Using a systematic approach, each applicable A and B 
recommendation from the USPSTF was addressed using point-
of-care testing (POCT), screening questionnaires, educational 
tools, or referrals to other health care providers.45   
Regardless of practice setting or methods to implement these 
services, pharmacists and student pharmacists need to be 
aware of some important considerations. First, legal 
considerations may be applicable.  For example, pharmacists 
may find there are some additional state or local requirements 
for POCT or other services.  Licensure, recordkeeping, and 
other legal ramifications may also exist depending on the type 
of initiative offered in the pharmacy, particularly if it involves 
POCT. Secondly, it may be prudent to investigate professional 
liability insurance coverage and obtain additional riders if 
necessary.  Thirdly, a documentation system must be in place. 
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Finally, billing for such services may be quite complex and 
multifaceted. Resources are available to not only help with a 
general understanding of billing, but also to support overall 
program implementation.40,46-48 
 
CONCLUSION  
Preventive health care services such as the clinical preventive 
services recommended by the USPSTF offer the opportunity to 
improve the health of populations and decrease health care 
costs.  Pharmacists and student pharmacists are well-
positioned to implement USPSTF recommendations, either 
through direct delivery of services or by providing education 
and referrals to other health care providers.  Many examples 
of successful pharmacy-based delivery of clinical preventive 
services have been published, providing insight and guidance 
to those interested in initiating such services at their practice 
site. 
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Table 1. USPSTF A and B recommendations (through November 30, 2016) for the general, 
non-pregnant, adult population that pharmacists and student pharmacists may be able to provide 
 
Topic USPSTF Recommendation  Grade 
Alcohol misuse: screening and 
counseling 
The USPSTF recommends that clinicians screen adults age 18 years or older 
for alcohol misuse and provide persons engaged in risky or hazardous 
drinking with brief behavioral counseling interventions to reduce alcohol 
misuse. 
 
B 
Aspirin preventive medication The USPSTF recommends initiating low-dose aspirin use for the primary 
prevention of cardiovascular disease and colorectal cancer in adults aged 50 
to 59 years who have a 10% or greater 10-year cardiovascular risk, are not 
at increased risk for bleeding, have a life expectancy of at least 10 years, 
and are willing to take low-dose aspirin daily for at least 10 years. 
 
B 
Blood pressure screening  The USPSTF recommends screening for high blood pressure in adults aged 
18 years or older. The USPSTF recommends obtaining measurements 
outside of the clinical setting for diagnostic confirmation before starting 
treatment. 
 
A 
Breastfeeding counseling The USPSTF recommends interventions during pregnancy and after birth to 
promote and support breastfeeding. 
 
B 
Depression screening The USPSTF recommends screening adults for depression when staff-
assisted depression care supports are in place to assure accurate diagnosis, 
effective treatment, and follow-up. 
 
B 
Diabetes screening The USPSTF recommends screening for abnormal blood glucose as part of 
cardiovascular risk assessment in adults aged 40 to 70 years who are 
overweight or obese.  
Clinicians should offer or refer patients with abnormal blood glucose to 
intensive behavioral counseling interventions to promote a healthful diet 
and physical activity. 
 
B 
Falls prevention in older adults: 
exercise or physical therapy 
The USPSTF recommends exercise or physical therapy to prevent falls in 
community-dwelling adults age 65 years and older who are at increased risk 
for falls. 
 
B 
Falls prevention in older adults: 
vitamin D 
The USPSTF recommends vitamin D supplementation to prevent falls in 
community-dwelling adults age 65 years and older who are at increased risk 
for falls. 
 
B 
Folic acid supplementation The USPSTF recommends that all women planning or capable of pregnancy 
take a daily supplement containing 0.4 to 0.8 mg (400 to 800 mcg) of folic 
acid. 
 
A 
Healthy diet and physical activity 
counseling  
The USPSTF recommends offering or referring adults who are overweight or 
obese and have additional cardiovascular disease (CVD) risk factors to 
intensive behavioral counseling interventions to promote a healthful diet 
and physical activity for CVD prevention. 
 
B 
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Topic USPSTF Recommendation  Grade 
Hepatitis C virus infection screening The USPSTF recommends screening for hepatitis C virus (HCV) infection in 
persons at high risk for infection. The USPSTF also recommends offering 
one-time screening for HCV infection to adults born between 1945 and 
1965. 
 
B 
HIV screening The USPSTF recommends that clinicians screen for HIV infection in 
adolescents and adults ages 15 to 65 years. Younger adolescents and older 
adults who are at increased risk should also be screened. 
 
A 
Intimate partner violence screening The USPSTF recommends that clinicians screen women of childbearing age 
for intimate partner violence, such as domestic violence, and provide or 
refer women who screen positive to intervention services. This 
recommendation applies to women who do not have signs or symptoms of 
abuse. 
 
B 
Obesity screening and management The USPSTF recommends screening all adults for obesity. Clinicians should 
offer or refer patients with a body mass index of 30 kg/m2 or higher to 
intensive, multicomponent behavioral interventions. 
 
B 
Osteoporosis screening The USPSTF recommends screening for osteoporosis in women age 65 years 
and older and in younger women whose fracture risk is equal to or greater 
than that of a 65-year-old white woman who has no additional risk factors. 
B 
Sexually transmitted infections 
behavioral counseling 
The USPSTF recommends high-intensity behavioral counseling to prevent 
sexually transmitted infections (STIs) in all sexually active adolescents and 
for adults at increased risk for STIs. 
 
B 
Statin preventive medication The USPSTF recommends that adults without a history of cardiovascular 
disease (CVD) use a low- to moderate-dose statin for the prevention of CVD 
events and mortality when all of the following criteria are met: 1) they are 
aged 40 to 75 years; 2) they have 1 or more CVD risk factors (ie, 
dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a 
calculated 10-year risk of a cardiovascular event of 10% or greater. 
 
B 
Skin cancer behavioral counseling The USPSTF recommends counseling children, adolescents, and young 
adults ages 10 to 24 years who have fair skin about minimizing their 
exposure to ultraviolet radiation to reduce risk for skin cancer. 
 
B 
Tobacco use counseling and 
interventions 
The USPSTF recommends that clinicians ask all adults about tobacco use, 
advise them to stop using tobacco, and provide behavioral interventions 
and U.S. Food and Drug Administration (FDA)–approved pharmacotherapy 
for cessation to adults who use tobacco. 
 
A 
Tuberculosis screening The USPSTF recommends screening for latent tuberculosis infection in 
populations at increased risk. 
B 
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Table 2. USPSTF A and B recommendations (through November 30, 2016) for the general, non-pregnant,  
adult population for which pharmacists and student pharmacists may serve as a source of education and/or referral 
 
Topic USPSTF Recommendation  Grade 
Abdominal aortic aneurysm screening The USPSTF recommends one-time screening for abdominal aortic 
aneurysm by ultrasonography in men ages 65 to 75 years who have ever 
smoked. 
B 
BRCA risk assessment 
and genetic counseling/testing 
The USPSTF recommends that primary care providers screen women who 
have family members with breast, ovarian, tubal, or peritoneal cancer with 
one of several screening tools designed to identify a family history that may 
be associated with an increased risk for potentially harmful mutations in 
breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive 
screening results should receive genetic counseling and, if indicated after 
counseling, BRCA testing. 
B 
Breast cancer preventive medications The USPSTF recommends that clinicians engage in shared, informed 
decision-making with women who are at increased risk for breast cancer 
about medications to reduce their risk. For women who are at increased risk 
for breast cancer and at low risk for adverse medication effects, clinicians 
should offer to prescribe risk-reducing medications, such as tamoxifen or 
raloxifene. 
B 
Breast cancer screening USPSTF recommends biennial screening mammography for women aged 50 
to 74 years.  
B 
Cervical cancer screening The USPSTF recommends screening for cervical cancer in women ages 21 to 
65 years with cytology (Pap smear) every 3 years or, for women ages 30 to 
65 years who want to lengthen the screening interval, screening with a 
combination of cytology and human papillomavirus (HPV) testing every 5 
years. 
A 
Chlamydial infection screening The USPSTF recommends screening for chlamydial infection in all sexually 
active nonpregnant young women age 24 years and younger and for older 
nonpregnant women who are at increased risk. 
A 
Colorectal cancer screening The USPSTF recommends screening for colorectal cancer using fecal occult 
blood testing, sigmoidoscopy, or colonoscopy in adults beginning at age 50 
years and continuing until age 75 years. The risks and benefits of these 
screening methods vary.   
A 
Gonorrhea screening The USPSTF recommends that clinicians screen all sexually active women, 
including those who are pregnant, for gonorrhea infection if they are at 
increased risk for infection (that is, if they are young or have other 
individual or population risk factors). 
B 
Hepatitis B screening The USPSTF recommends screening for hepatitis B virus infection in persons at high risk for infection. B 
Lung cancer screening 
The USPSTF recommends annual screening for lung cancer with low-dose 
computed tomography in adults ages 55 to 80 years who have a 30 pack-
year smoking history and currently smoke or have quit within the past 15 
years. Screening should be discontinued once a person has not smoked for 
15 years or develops a health problem that substantially limits life 
expectancy or the ability or willingness to have curative lung surgery. 
B 
Syphilis screening The USPSTF strongly recommends that clinicians screen persons at 
increased risk for syphilis infection. 
A 
 
